Peptide receptor radionuclide therapy of neuroendocrine tumors
Arveschoug, A.K.; Hjorthaug, K.; Rehling, M.; Højgaard, L.; Mortensen, J.; Oturai, P.S.
Ugeskrift for Laeger 171(13): 1073
2009
ISSN/ISBN: 1603-6824 PMID: 19321068 Document Number: 630280
Document emailed within 1 workday
Related Documents
Bodei, L.; Pepe, G.; Paganelli, G. 2010: Peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors with somatostatin analogues European Review for Medical and Pharmacological Sciences 14(4): 347-351Papamichail, D.G.; Exadaktylou, P.E.; Chatzipavlidou, V.D. 2016: Neuroendocrine tumors: Peptide receptors radionuclide therapy (PRRT) Hellenic Journal of Nuclear Medicine 19(1): 75-82
Pelosi, G.; Volante, M.; Papotti, M.; Sonzogni, A.; Masullo, M.; Viale, G. 2006: Peptide receptors in neuroendocrine tumors of the lung as potential tools for radionuclide diagnosis and therapy Quarterly Journal of Nuclear Medicine and Molecular Imaging: Official Publication of the Italian Association of Nuclear Medicine and the International Association of Radiopharmacology and Section of the Society Of. 50(4): 272-287
Cremonesi, M.; Ferrari, M.; Di Dia, A.; Botta, F.; De Cicco, C.; Bodei, L.; Paganelli, G. 2011: Recent issues on dosimetry and radiobiology for peptide receptor radionuclide therapy Quarterly Journal of Nuclear Medicine and Molecular Imaging: Official Publication of the Italian Association of Nuclear Medicine and the International Association of Radiopharmacology and Section of the Society Of. 55(2): 155-167
Panigone, S.; Nunn, A.D. 2006: Lutetium-177-labeled gastrin releasing peptide receptor binding analogs: a novel approach to radionuclide therapy Quarterly Journal of Nuclear Medicine and Molecular Imaging: Official Publication of the Italian Association of Nuclear Medicine and the International Association of Radiopharmacology and Section of the Society Of. 50(4): 310-321
Parisella, M.G.; Chianelli, M.; D'Alessandria, C.; Todino, V.; Mikolajczak, R.; Papini, E.; Dierckx, R.A.; Scopinaro, F.; Signore, A. 2012: Clinical indications to the use of (99m)Tc-EDDA/HYNIC-TOC to detect somatostatin receptor-positive neuroendocrine tumors Quarterly Journal of Nuclear Medicine and Molecular Imaging: Official Publication of the Italian Association of Nuclear Medicine and the International Association of Radiopharmacology and Section of the Society Of. 56(1): 90-98
Virgolini, I.; Traub, T.; Leimer, M.; Novotny, C.; Pangerl, T.; Ofluoglu, S.; Halvadjieva, E.; Smith-Jones, P.; Flores, J.; Li, S.R.; Angelberger, P.; Havlik, E.; Andreae, F.; Raderer, M.; Kurtaran, A.; Niederle, B.; Dudczak, R. 2000: New radiopharmaceuticals for receptor scintigraphy and radionuclide therapy Quarterly Journal of Nuclear Medicine: Official Publication of the Italian Association of Nuclear Medicine and the International Association of Radiopharmacology 44(1): 50-58
Gerasimou, G.; Moralidis, E.; Gotzamani-Psarrakou, A. 2010: Somatostatin receptor imaging with (111)In-pentetreotide in gastro-intestinal tract and lung neuroendocrine tumors-Impact on targeted treatment Hellenic Journal of Nuclear Medicine 13(2): 158-162
Phan, A.T.; Yao, J.C. 2008: Neuroendocrine tumors: novel approaches in the age of targeted therapy Oncology 22(14): 1617-1623; Discussion: 1623-1624, 1629
De Jong, M.; Breeman, W.A.; Bernard, H.F.; Kooij, P.P.; Slooter, G.D.; Van Eijck, C.H.; Kwekkeboom, D.J.; Valkema, R.; Mäcke, H.R.; Krenning, E.P. 1999: Therapy of neuroendocrine tumors with radiolabeled somatostatin-analogues Quarterly Journal of Nuclear Medicine: Official Publication of the Italian Association of Nuclear Medicine and the International Association of Radiopharmacology 43(4): 356-366
Gouyon, B.; Ruszniewski, P. 1995: Chemoembolization, immunotherapy and hormone therapy of carcinoid and digestive neuroendocrine tumors Annales de Gastroenterologie et d'Hepatologie 31(2): 121-123
Otte, A.; Herrmann, R.; Mäcke, H.R.; Müller-Brand, J. 1999: Yttrium 90 DOTATOC: a new somatostatin analog for cancer therapy of neuroendocrine tumors Praxis 88(31-32): 1263-1268
Vandenbark, A.A.; Bourdette, D.N.; Whitham, R.; Chou, Y.K.; Hashim, G.A.; Offner, H. 1993: T-cell receptor peptide therapy in EAE and MS Clinical and Experimental Rheumatology 11(Suppl 8): S51-S53
Darbà, J.; Ascanio, M. 2019: Therapy for Gastroenteropancreatic Neuroendocrine Tumors: drug evaluation reports review in Spain Neuro Endocrinology Letters 39(8): 537-543
Shomali, M.E. 2009: Practical applications of therapy with a glucagon-like peptide-1 receptor agonist Journal of Family Practice 58(9 Suppl Treating): S35-S43
Hemmingson, A.; Johansson, H.; Lindgren, P.G.; Lundqvist, G.; Lörelius, L.E.; Wide, L.; Wilander, E.; Oberg, K. 1984: Peptide-producing tumors in the pancreas and gastrointestinal tract: syndrome, survey, therapy Lakartidningen 81(35): 3015-3021
Shubrook, J.H. 2018: Advances in Type 2 Diabetes: Focus on Basal Insulin/Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy Journal of Family Practice 67(8 Suppl): S49-S54
Yasufuku-Takano, J.; Takano, K. 2011: Pathogenesis and molecular genetics of carcinoid tumors/gastrointestinal neuroendocrine tumors Nihon Rinsho. Japanese Journal of Clinical Medicine 69(Suppl 2): 629-634
Weber, M. 2014: New directions in the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): shifting from symptom management to targeting tumors Clinical Advances in Hematology and Oncology: H&o 12(12 Suppl 19: 12-17
Zaks, T.Z.; Rosenberg, S.A. 1998: Immunization with a peptide epitope (p369-377) from HER-2/neu leads to peptide-specific cytotoxic T lymphocytes that fail to recognize HER-2/neu+ tumors Cancer Research 58(21): 4902-4908